All News
72% of you would treat some high-risk subclinical arthralgias with MTX
and Marta Mosca, in the #EULAR2022 highlights, broadly agrees
OP0070 Leiden data showed better function and presenteeism. And that’s a win in my book
@RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71
David Liew drdavidliew ( View Tweet)
Biosimilars and COVID vaccines have made nocebo more pertinent than ever.
How do we combat it?
First line is good communication, and the foot soldiers are the right phrases.
Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G
David Liew drdavidliew ( View Tweet)
#OP0004 #EULAR2022 In line with EULAR President’s preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network @RheumNow https://t.co/h03mieTcQt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.
In the 2022 version:
JAKi now separate sentence following bDMARDs, with proviso to mention risk.
Sometimes guidelines have to tell us what we’ve all inevitably been expecting
#EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
David Liew drdavidliew ( View Tweet)
#EULAR2022 POS0285
130K UK patients had incident gout bw 2004-2020
⭐️Only 29% started on ULT w/in 12 mos
⭐️Target urate level only 14% in 2004, only to 17% in 2020
Updated EULAR guidelines in 2016: No statistical difference in ULT Rx or target attainment
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA.
@RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Robert B Chao, MD doctorRBC ( View Tweet)
RheumNow’s coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Rituximab/belimumab patients & COVID vaccination response:
may have had average antibody response
but there’s still the cellular response to consider too! Not as bad.
Still caution++, but when ritux really needed we’ll find a way despite COVID
from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG
David Liew drdavidliew ( View Tweet)
#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings.
Existing MRI scoring may underserve axSpA in women.
Added to therapy differences, a lot to readdress for our female axSpA patients.
from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM
David Liew drdavidliew ( View Tweet)
#highlight n•1 💫
The presence of specific peripheral blood T cell sub-populations associated w/ disease flares
in RA pts in remission after cs or bioDMARDs tapering or cessation
identified in 2 different abstracts
OP0011 and OP0074
@RheumNow #EULAR2022 https://t.co/SO2AgtkyTP
Aurelie Najm AurelieRheumo ( View Tweet)
Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity.
So much more to digest....
@RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 POS0282
Febuxostat vs allopurinol: CV risk population study
⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction
⭐️CV safety non-inferior to allopurinol
@Rheumnow https://t.co/1oDSioQWPT
Eric Dein ericdeinmd ( View Tweet)
Stimakovits et al. Influence of placebo vs active comparator in RA clinical trials. ACR response rates systematically higher in studies with active comparators. ACR20 OR 1.64 (1.44-1.86), ACR50 OR 1.46 (1.28-1.71), ACR70 OR 1.61 (1.28-2.02) @RheumNow #EULAR2022 POS0563 https://t.co/x7PQH11oue
Richard Conway RichardPAConway ( View Tweet)
We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go…
because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander.
Understanding TNFi resistance is path to:
predicting it
knowing best what to do with it
@RheumNow https://t.co/22Y6iinSbH
David Liew drdavidliew ( View Tweet)
Psoriasis and Psoriatic arthritis patients have different circulating microRNA signatures compared to healthy controls.
(miRNAs: non-coding RNAs controlling gene expression)
PsO/PsA miRNAs involved in bone metabolism
@RheumNow #EULAR2022 ABST#POS0314
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 POS0283: Do Rheums have Gout Stigma?
⭐️Stereotypes about pt related factors
⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L
Links:
Richard Conway RichardPAConway ( View Tweet)
PMR on the podium @profbdasgupta, with a positive phase 3!
Sarilumab in relapsing PMR (SAPHYR):
sari q2w+14w taper vs placebo+52w taper
underrecruited 118/280 (COVID) but still hit primary, almost all secondary
Better outcome + steroid-sparing: big
LB0006 #EULAR2022 @RheumNow https://t.co/nd3TSibYa0
David Liew drdavidliew ( View Tweet)
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
